Coeptis Therapeutics Holdings, Inc.

    Coeptis Therapeutics Holdings, Inc.

    NNASDAQ:COEP
    - -
    USD
    - -
    - -
    Coeptis Therapeutics Holdings, Inc.
    NASDAQ:COEP
    (Nasdaq Stock Market)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2020
    2021
    2022
    2023
    2024
    2025
    TTM
    USD
    0.03
    0.07
    - -
    - -
    - -
    - -
    0.35
    Revenue per Share
    -8.96
    -13.16
    -52.57
    -16.56
    -5.55
    - -
    -2.84
    Basic EPS, GAAP
    -3.07
    -6.1
    -5.42
    -5.64
    -3.45
    - -
    -2.24
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -13.79
    -26.95
    -92.46
    -68.01
    -50.94
    - -
    -28.62
    Book Value per Share
    -5.03
    2.3
    6.23
    0.63
    1.73
    - -
    3.42
    Tangible Book Value per Share
    1
    1
    1
    1
    2
    - -
    4
    Basic Weighted Avg Shares
    - -
    - -
    - -
    - -
    - -
    1
    1
    Sales/Revenue/Turnover
    -21,823.77
    -18,727.91
    - -
    - -
    - -
    -956.94
    -956.94
    Operating Margin (%)
    - -
    - -
    1
    1
    1
    1
    1
    Depreciation Expense
    -9
    -13
    -38
    -21
    -11
    -12
    -11
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    -29,765.89
    -17,932.37
    - -
    - -
    - -
    -874.29
    -800.38
    Profit Margin (%)
    -5
    -1
    2
    -1
    -3
    6
    6
    Working Capital
    - -
    2
    - -
    - -
    - -
    - -
    - -
    LT Debt
    -5
    2
    4
    1
    4
    14
    14
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    ST Debt
    1
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    4
    5
    6
    Market Capitalization
    23
    67
    55

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    Total Current Assets
    4
    6
    7
    Cash, Cash Equivalents & STI
    3
    5
    6
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    4
    3
    2
    Payables & Accruals
    1
    1
    1
    ST Debt
    1
    - -
    - -
    Deferred Revenue
    2
    1
    1

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    100.18%
    263.78%
    Free Cash Flow
    - -
    33.82%
    29.38%
    Net Income, GAAP
    - -
    28.93%
    11.58%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    1
    1

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -7.92
    -2.94
    -4.77
    - -
    -16.56
    2024
    -0.08
    -1.62
    -0.87
    - -
    -5.55
    2025
    -1
    -0.95
    -0.58
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • prnewswire.com

      Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market

    • globenewswire.com

      Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

    • globenewswire.com

      Coeptis Receives Shareholder Approval Towards Z Squared Merger

    • globenewswire.com

      Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

    • defenseworld.net

      Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 3.6% – Time to Sell?

    • globenewswire.com

      Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

    • globenewswire.com

      Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

    • globenewswire.com

      Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

    • globenewswire.com

      Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

    • globenewswire.com

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders

    • prnewswire.com

      SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP

    • businesswire.com

      COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders

    • globenewswire.com

      Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

    • globenewswire.com

      COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

    • globenewswire.com

      Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

    • globenewswire.com

      COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

    • businesswire.com

      NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

    • globenewswire.com

      COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

    • globenewswire.com

      COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

    • globenewswire.com

      COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing